Page 22 - 2024 BRAVO! TAIWAN_en

health data, promoting cross-domain scientific and health improvement, and medication for diseases in
technological innovation, carrying out comprehensive the Asia-Pacific market has increased significantly.
epidemic prevention scientific and technological Foreign investors can make use of Taiwan's
capabilities, expanding international biomedical geographical advantage, talent, and technology
business opportunities and other key strategic parks, as well as government support measures,
groundwork with the aim of developing Taiwan's such as tax incentives and R&D subsidies as
vision of health for all ages. specified in the "Act for the Development of Biotech
In order to improve the industrial development and Pharmaceutical Industry." Taiwan aims to be
environment and emphasize equal emphasis a production base and regional headquarters for
on R&D and manufacturing, the Act for the accelerated entry into the Asia-Pacific market.
Development of Biotech and Pharmaceutical ¾ Investment Opportunities for New
Industry was revised and officially announced in Pharmaceuticals/Emerging Medical
2021 to encourage innovative medical equipment, Treatments
new pharmaceuticals, emerging medical treatments Taiwan has an excellent healthcare system, plentiful
(precision medicine, regenerative medicine, clinical capabilities and a strong information and
smart medicine) and Contract Development and communications technology (ICT) industry. With a
Manufacturing Organization (CDMO) development. comprehensive industrial chain of small molecule
Promoting our vision: Establish Taiwan as a and protein pharmaceuticals, as well as a solid
benchmark for global precision health and prevention foundation of R&D, manufacturing, and international
technology. service capabilities, Taiwan is well positioned for
business opportunities in new pharmaceutical and
Investment Opportunities emerging medical treatments.

¾ Investment Opportunities in Medical
¾ Opportunities in the Rapid Growth of Devices
the Domestic Market
The supply chain for the development of Type
Taiwan's biomedical industry revenues are estimated II medical devices (including smart assistive
to have exceeded NT$750 billion in 2023, with a devices, minimally invasive surgical imaging,
growth rate of more than 7%. Annual pharmaceutical orthopedics, dental materials, cell therapy, cranial
industry revenues have grown 34% over 2022, and cardiovascular medicine and ophthalmology)
as the number of new pharmaceuticals on the in Taiwan is mature, and opportunities are actively
international market has increased and export sales being sought for cooperation in system integration
of generic drugs have grown. In addition, investment and the development of high-end and high-
in advanced medical technologies such as digital value medical equipment. Foreign companies
medicine and regenerative medicine continues that invest in Taiwan will be able to accelerate
to increase, with products being approved for the development and marketing of products with
marketing and gradually introduced into medical high quality and fair prices. Backed by Taiwan's
institutions for use. This will help improve the marketing experience, they will be able to sell their
accuracy of treatments and cure rates, and become products in China and other emerging markets.
a new impetus for biotech pharmaceutical industry
development. ¾ Investment Opportunities in Health Care
¾ Investment in Taiwan for Asia-Pacific In 2025, Taiwan is expected to become a super aging
Deployment society. Taiwan is laying a foundation for medical
With the growth of Asia's elderly population and the trials, and is adapting its policies and regulations to
provide for more flexibility. These changes, combined
rise of emerging economies in China and Southeast with innovative service models from both domestic
Asia, the demand for basic medical care, home care, and foreign companies, will create advantages
for new business opportunities in services for
older people. Taiwan's high quality healthcare
system and solid ICT foundation are conducive to
the establishment of infrastructure for supporting
environmental systems, such as monitoring service
platforms, information system services, and
integrated platforms for smart health services.

20